Abstract
Endometriosis is an enigmatic disease characterized by pain and infertility in which endometrial tissue grows in ectopic locations, predominantly the pelvic cavity. The pathogenesis and pathophysiology of endometriosis is complex and postulated to involve alterations in inflammatory, cell proliferation and post-transcriptional regulatory pathways among others. Our understanding on the pathogenesis and pathophysiology of endometriosis is further complicated by the fact that endometriosis can only be diagnosed by laparoscopy only after the disease has manifested. This makes it difficult to understand the true pathogenesis as a cause-and-effect relationship is difficult to ascertain. To aid in our understanding on endometriosis pathogenesis and pathophysiology, numerous rodent models have been developed. In this case, we discuss further assessment of a miR-451a—macrophage migration inhibitory factor (Mif) pathway which contributes to lesion survival. Specifically, we evaluate the temporal expression of lesion Mif receptors, Cd74 and Cxcr4 using host mice which express wild-type or miR-451a deficient lesions. Similar to that observed in humans and a non-human primate model of endometriosis, Cd74 expression is elevated in lesion tissue in a temporal fashion while that of Cxcr4 shows minimal increase during initial lesion establishment but is reduced later during the lifespan. Absence of miR-451a during initial lesion establishment is associated with an augmentation of Cd74, but no Cxcr4 expression. The data obtained in this study provide further support for a role of Mif receptors, Cd74 and Cxcr4 in the pathophysiology of endometriosis.
Keywords: endometriosis, experimental model, miR-451a, MIF, CD74
1. Introduction
1.1. Endometriosis Pathogenesis and Pathophysiology
Endometriosis is an estrogen-dependent, chronic, benign gynecological disease in which endometrial glands and stroma establish in the peritoneal cavity. Endometriosis occurs in approximately 10% of women of reproductive age and is characterized by pelvic pain and infertility [1,2]. Several theories and contributing factors have been proposed in the pathogenesis of this disease. For example, accumulating evidence suggests a role for endometrial stem cells, a dysfunctional immune response, genetic predisposition, aberrant peritoneal environment and alterations in the eutopic endometrium [3,4]. Pathological mechanisms are complex and include abnormal hormonal, epigenetic, genetic, and immunologic/inflammatory pathways among others [1,2,3,4]. One of the greatest challenges in understanding the pathogenesis and pathophysiology of endometriosis stems from the fact that the disease can only be diagnosed after it has manifested. This creates a conundrum of cause and effect making it difficult to establish if the altered physiology of lesion tissue is a result of or a contributing factor in lesion establishment and survival. To overcome this issue, experimental models have been developed in rodents as well as non-human primates, with the former providing the advantage of being able to genetically modify the tissue donor or recipient host to dissect the role of specific genes in endometriosis pathophysiology.
1.2. Syngeneic Mouse Models to Study Endometriosis Pathophysiology
Numerous mouse models have been developed to study endometriosis. Burns and colleagues [5] provide a detailed review of “best fit” experimental mouse models for endometriosis and the reader is referred to this reference for greater detail. As emphasized in that review, for a “best fit” model, the host in which the disease is established should be immunocompetent and hormonally intact. Administration of exogenous estrogen/estradiol (E2) to the host, often used to promote lesion establishment and survival should ideally be avoided to prevent masking or confounding of study endpoints. With this in mind, we developed one of the first immune competent, reproductively intact mouse models for endometriosis study that avoided administration of exogenous E2 to host mice [6]. Figure 1 depicts the general procedure for induction of experimental disease based upon this concept.
1.3. miR-451a-MIF Pathway in Endometriosis Pathophysiology
It is well established that microRNAs (miRNAs) play a role in the pathophysiology of endometriosis reviewed in [7,8,9]. miRNAs are small, non-coding RNAs which function as epigenetic regulators that modulate gene expression post-transcriptionally [10,11]. Cell proliferation, invasion and apoptosis are all events conducive to endometriosis development and survival [12] and miRNAs have been implicated to play a vital role in these events. As a result, researchers have compiled miRNA expression profiles for endometriosis in both the disease tissue and eutopic endometrium as well as control patients [13,14,15,16]. These data were integral in developing our understanding on their potential role in endometriosis pathophysiology which to date continues to emerge. Of the numerous miRNAs mis-expressed in endometriotic tissue, miR-451a (originally identified as miR-451) is one of the more well-studied miRNAs [17,18,19,20,21,22].
Similar to most miRNAs, miR-451a is a putative regulator of hundreds of mRNA transcripts. Perhaps most relevant to the pathophysiology of endometriosis is the putative cytokine target, macrophage migration inhibitory factor (MIF). Endometritoic lesions cells are a rich source of MIF which exhibits mitogenic activity promoting the growth of endothelial cells [23] as well as the ability to stimulate prostaglandin E2, cyclooxygenase-2 [24], vascular endothelial growth factor, interleukin-8 and monocyte chemotactic protein-1 [25]. These cytokines are associated with a proliferative and angiogenic phenotype conducive to endometriotic establishment, growth and survival. In addition, MIF is predominantly expressed in glandular epithelial cells of both eutopic endometrium [26,27] and robustly expressed in epithelium of active and early/stage I endometriotic lesions [27] with focal stromal staining in both tissue types. Two independent studies [6,28] utilized experimental mouse models for endometriosis to demonstrate that Mif plays an active role in endometriosis pathophysiology as administration of the MIF antagonist, ISO-1, reduced endometriotic lesion size.
For MIF to elicit a biological response it must bind with cell surface receptors. CD74 (also referred to as invariant chain) was identified as the first receptor for MIF [29]. CD74 (along with CD44) was demonstrated to be responsible for MIF liberation of angiogenic factors in vitro, ref. [25] and our in vivo studies in humans as well as a baboon model for endometriosis [30] demonstrate that CD74 is robustly expressed in endometriotic lesion tissue. Additionally, C-X-C chemokine receptor type 4 (CXCR4) has been shown to function as a non-canonical MIF receptor in several cell types [31,32,33,34]. With respect to endometriosis, CXCR4 transcript and protein is expressed in human endometriotic lesion tissue [35,36,37] including deep-infiltrating lesions [38], but its association with CD74 has not been assessed in experimental models for endometriosis. Based upon these observations, the objective of the current study was to concurrently assess expression of Cd74 and Cxcr4 in endometriotic lesion tissue from mice with experimentally-induced disease to see if we could recapitulate a similar pattern of expression observed in human disease.
2. Materials and Methods
2.1. Experimental Mouse Model for Endometriosis
All animal experiments were conducted at the University of Kansas Medical Center under the guidance of Dr. Nothnick following the relevant guidelines and regulations. Experimental procedures incorporating animals were approved by the University of Kansas Medical Center Institutional Animal Care and Use Committee (IACUC). Experimental endometriosis was induced as depicted in Figure 1.
Briefly, donor female mice consisted of 22- to 24-day old C57BL/6 female mice. These females were either wild-type C57BL/6 or females deficient for miR-451a/miR-144-3p. To stimulate endogenous estrogen production and subsequent estrogenic responses within the uterus, all donor females were injected s.c. with pregnant mare serum gonadotropin (PMSG; 2 IU; Sigma Chemical Company, St. Louis, MO, USA). Uteri were then harvested from donor mice approximately 40–42 h after PMSG administration (Figure 1, step a). Each uterus was cut into 6 equal size fragments (Figure 1, step b) and protruding endometrial tissue (stroma and epithelium) was separated from myometrium with the aid of a dissecting microscope (Figure 1, step c). Protruding endometrial tissue (which contained stromal as well as glandular and luminal epithelium) was first cut into halves (Figure 1, step d) to yield 12 fragments of equal size (1 mm3; Figure 1, step e). Uterine fragments were prepared for transfer to recipients (Figure 1, step f) by resuspending in 0.4 mL of sterile saline. Recipient mice (2- to 4-month old wild-type C57BL/6 immuno-competent, reproductively intact females, which express miR-451a/miR-144-3p) were anesthetized with ketamine/xylazine and an antibiotic ointment was placed over the corneas to avoid corneal abrasions. The area over the right rib cage was prepared for surgery and a small incision (approximately 0.5 cm) was made exposing the peritoneal cavity. Tissue fragments resuspended in PBS were injected into the peritoneal cavity through the incision (Figure 1, step f) and the incision was then closed with wound clips. Carprofen analgesic was given post-operatively at the conclusion of the surgery and again 24 h later. Mice were then sacrificed at indicated time post endometriosis induction (Figure 1, step g) and lesions processed for mRNA isolation in this experiment (Figure 1, step h). Week 0 controls consisted of endometrial fragments which were not transferred to recipient mice and were immediately placed into Trizol (Life Technologies, Carlsbad, CA, USA) and subjected to RNA isolation as described below.
2.2. RNA Isolation and qRT-PCR of miRNAs and mRNAs
Endometriotic lesions were harvested at the indicated time points and RNA was isolated from tissue using Trizol (1.0 mL of Trizol/100 mg of tissue) following the protocols provided by the manufacturer. Total RNA was reversed transcribed using 1 µg of total RNA using reverse transcription (RT) kits (Applied Biosystems; Foster City, CA, USA) following the manufacturer’s protocol. Primers for mouse Cd74 and Cxcr4 were designed using Primer-Blast and synthesized by Integrated DNA Technology (IDT, Coralville, IA, USA) and sequences are listed in Table 1. Cd74 and Cxcr4 expression levels were normalized to 18S rRNA using primers from Applied Biosystems (Table 1).
Table 1.
All qRT-PCR reactions were completed on a QuantStudio7 Flex Real-Time PCR System (Applied Biosystems). All samples were run in triplicate and the average value used in subsequent calculations. The 2-delta-delta CT method was used to calculate the fold-change values among samples as previously described by our group [17,18,20,30]. qRT-PCR intra- and inter-assay coefficients of variation were both less than 6%.
2.3. Statistical Analysis
Data were first assessed for normal (Gaussian) distribution. All data failed to exhibit Gaussian distribution and were therefore transformed to log2 scale with analysis conducted as described in each Figure legend. All analysis was conducted using GraphPad Instat3 (GraphPad Software, La Jolla, CA, USA). Significance was set at p < 0.05 for all analyses.
3. Results
We first examined endometriotic lesion expression of the cognate Mif receptor, Cd74 in endometriotic lesion tissue derived from wild-type and miR-451a/miR-144-3p deficient tissue. Cd74 mRNA expression increased from 1 through 8 weeks post-endometriosis induction (week 0) but there was high variation among the fold increase in expression. In order, to make variation similar across orders of magnitude, data were log2 transformed and are presented in Figure 2. In mice with wild-type (WT) lesions, Cd74 expression increased at 1 to 2 weeks post-induction reaching statistically higher levels of expression at weeks 4 and 8 with a maximal increase of 6-fold compared to week 0. When miR-451a deficient tissue was used to develop ectopic lesions, there was a more robust up-regulation of Cd74 expression compared to that of WT lesions. Specifically, Cd74 expression increased approximately 8-fold, 1 to 2 weeks post-induction, reaching peak levels between weeks 4 and 8 as high as 194-fold above week 0 levels. In these same samples (for the 0-to-4-week timepoints) reduced levels of Mif expression were associated with elevated miR-451a expression. Compared to human disease, our mouse model closely replicates the pattern of expression of endometriotic lesion miR-451a, Mif and Cd74 expression observed in human endometriotic lesion tissue.
In contrast to Cd74, Cxcr4 mRNA expression (Figure 3) slightly increased at 1 week from induction (1.43-fold increase, p = 0.093) with minimal increase (p < 0.05) from weeks 2- and 4-weeks post-endometriosis induction (week 0) in mice with WT lesions. However, at week 8, Cxcr4 expression was significantly less compared to all other time points (p < 0.05; Figure 3).
Compared to WT lesions, lesions developed from miR-451a deficient tissue exhibited a significant increase at 1-week post-induction and this increase remained significantly elevated through week 8 post-induction. In comparison to Cd74 levels, Cxcr4 levels were approximately 30-fold less abundant in lesion tissue from WT mice and 180-fold less abundant in lesions derived from miR-451a deficient tissue.
4. Discussion
Experimental mouse models are essential for enhancing our understanding on endometriosis pathophysiology [5]. The mouse model which we initially described in 2011 [6] consists of using PMSG-primed endometrial tissue from immature, immune competent, reproductively intact donors. Using this model, physiological levels of endogenous E2 are liberated which aids in the establishment of ectopic lesions (endometrial tissue from either unstimulated or PMSG + hCG, the latter in which progesterone levels are elevated, do not establish ectopically). Using mature (2–4 months of age), immune competent, reproductively intact, non-hormonally stimulated host mice has several advantages. First, exogenous E2 is not provided allowing for normal hormonal changes which occur during a reproductive cycle, which more closely mimics that in patients. This in turn allows for examination of endpoints of interest under hormonal levels which are more representative compared to supraphysiological levels of E2. Second, host mice are immune competent which again more closely mimics the human peritoneal environment and allows for assessment of the potential role of immune/inflammatory mediators in endometriosis pathophysiology. Third, a known number of endometrial fragments of a known size are transferred to recipient mice allowing for assessment of lesion growth over time. Lastly, using this mouse model, we can assess lesion dynamics as lesions first establish (week 1) through growth (weeks 2 to 4) and eventual regression.
With this in mind, we used wild-type or miR-451a deficient tissue to establish lesions in wild-type hosts to assess the natural progression of lesion expression of the Mif receptors, Cd74 and Cxcr4 over an eight-week timespan. Using this model, we report for the first-time concurrent assessment of both Cd74 and Cxcr4 expression in endometriotic lesion tissue from mice with experimentally-induced endometriosis. CD74 was the first reported cell surface receptor for MIF [29]. Veillat and colleagues [25] first reported that MIF could induce expression of angiogenic factors in endometriotic stromal cells and this effect could be attenuated by knockdown of CD74 expression. Mahdian and associates reported elevated MIF and CD74 mRNA expression in ectopic lesion tissue compared to eutopic endometrium from both control and patients with endometriosis [39], while we reported elevated CD74 protein expression and localization to glandular epithelium [30]. Thus, our observation of elevated Cd74 expression in our mouse model in which ectopic lesions were derived from wild-type tissue supports these prior reports which utilized human tissues, validating this experimental model.
As mentioned earlier, CXCR4 is capable of forming dimers with MIF-bound CD74 [31,32,33,34]; however, the majority of the studies which have evaluated CXCR4 in the context of endometriosis have been evaluating it as a receptor for CXCL12 [35,36]. A recent report by Tal and colleagues [39] used Cxcr4-deficient tissue to establish experimentally-induced endometriosis and found that, compared to control lesions (which expressed Cxcr4), less lesions developed but development was not completely inhibited. This observation coupled with our current observation that Cxcr4 expression is minimally elevated in experimental endometriosis may suggest that other receptors such as Cd74 may play a more prominent role in endometriotic lesions development and/or survival. Alternatively, other receptors capable of binding with MIF-CD74 complexes, such as CD44 [40,41,42] could also contribute to MIF signaling in endometriosis [43].
With respect to experimental endometriosis induced using miR-451a deficient tissue, we were intrigued to find augmented expression of Cd74 compared to levels of expression in wild-type lesions. However, we are uncertain as to what the mechanism for this up-regulation may be. It is tempting to speculate that the elevated expression of Cd74 may occur in response to the reduced levels of Mif ligand [20] in an attempt to maintain lesion survival. Accumulating data from our lab [18,20,44,45] support the notion that increased levels of endometriotic lesion miR-451a function to curtail lesion survival by at least impart reducing Mif expression but other indirect targets of miR-451a which impact lesion survival [44] may come into play as well. Alternatively, loss of miR-451a may lead to changes in other miRNAs which could lead to enhanced Cd74 transcript expression. We recently reported that miR-451a decreases expression of a miRNA (miR-25-3p) in vitro which is a bonafide regulator of PTEN expression [45]. Thus, it may be likely that expression levels of miR-451a (either absence at the time of lesion establishment or elevation which occurs as lesions age) may influence the expression of other miRNAs which could impact Cd74 expression. Clearly, more detailed assessment of the role of miR-451a, the MIF-pathway and other pathways modulated by miR-451a in the pathophysiology of endometriosis are warranted for study.
In summary, using a reproductively intact, immune competent mouse model of experimental endometriosis, we report lesion expression of Mif receptors Cd74 and Cxcr4. Cd74 is robustly expressed, and its expression increases with lesion growth and survival, expressing a similar pattern to that observed in humans as well as in a non-human primate model of experimental endometriosis. Use of this mouse model can be used in future studies to further explore the pathophysiology of endometriosis in making bench to bedside contributions which will enhance our understanding on the pathophysiology of endometriosis.
Author Contributions
Conceptualization, W.B.N.; methodology, W.B.N. and A.G.; formal analysis, W.B.N.; investigation, W.B.N. and A.G.; writing—original draft preparation, W.B.N.; writing—review and editing, W.B.N. and A.G.; Funding acquisition, W.B.N. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Animal studies were approved and conducted according to the guidelines of the Declaration of Helsinki and approved by Institutional Animal Care and Use Committee (IACUC) of the University of Kansas Medical Center. (2022-2541; 21 January 2020).
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Funding Statement
Research findings reported in this study were funded in part from NIH grant R01 HD069043 to W.B.N.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Smolarz B., Szyłło K., Romanowicz H. Endometriosis: Epidemiology, classification, pathogenesis, treatment and genetics review of the literature. Int. J. Mol. Sci. 2021;22:10554. doi: 10.3390/ijms221910554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Burney R.O., Giudice L.C. Pathogenesis and pathophysiology of endometriosis. Fertil. Steril. 2012;98:511–519. doi: 10.1016/j.fertnstert.2012.06.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Giudice L.C., Kao L.C. Endometriosis. Lancet. 2004;364:1789–1799. doi: 10.1016/S0140-6736(04)17403-5. [DOI] [PubMed] [Google Scholar]
- 4.Sourial S., Tempest N., Hapangama D.K. Theories on the pathogenesis of endometriosis. Int. J. Reprod. Med. 2014;2014:179515. doi: 10.1155/2014/179515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Burns K.A., Pearson A.M., Slack J.L., Por E.D., Scribner A.N., Eti N.A., Burney R.O. Endometriosis in the mouse: Challenges and progress toward a “best fit” murine model. Front. Physiol. 2022;12:806574. doi: 10.3389/fphys.2021.806574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nothnick W.B., Colvin A., Cheng K.F., Al-Abed Y. Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. J. Endometr. 2011;3:135–142. doi: 10.5301/JE.2011.8910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nasu K., Aoyagi Y., Zhu R., Okamoto M., Yano M., Kai K., Kawano Y. Role of repressed microRNAs in endometriosis. Med. Mol. Morph. 2022;55:1–7. doi: 10.1007/s00795-021-00303-8. [DOI] [PubMed] [Google Scholar]
- 8.Bjorkman S., Taylor H.S. MicroRNAs in endometriosis: Biological function and emerging biomarker candidates. Biol. Reprod. 2019;100:1135–1146. doi: 10.1093/biolre/ioz014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Nothnick W.B. MicroRNAs and endometriosis: Distinguishing drivers from passengers in disease pathogenesis. Semin. Reprod. Med. 2017;35:173–180. doi: 10.1055/s-0037-1599089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanisms, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
- 11.Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–1934. doi: 10.1126/science.1149460. [DOI] [PubMed] [Google Scholar]
- 12.Erson P.A., Petty E.M. MicroRNAs in development and disease. Clin. Genet. 2008;74:296–306. doi: 10.1111/j.1399-0004.2008.01076.x. [DOI] [PubMed] [Google Scholar]
- 13.Filigheddu N., Gregnanin I., Porporato P.E., Surico D., Perego B., Galli L., Patrignani C., Graziani A., Surico N. Differential expression of microRNAs between eutopic and ectopic endometrium in ovarian endometriosis. J. Biomed. Biotechnol. 2010;2010:369549. doi: 10.1155/2010/369549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ohlsson Teague E.M., Van der Hoek K.H., Van der Hoek M.B., Perry N., Wagaarachchi P., Robertson S.A., Print C.G., Hull L.M. MicroRNA-regulated pathways associated with endometriosis. Mol. Endocrinol. 2009;23:265–275. doi: 10.1210/me.2008-0387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hawkins S.M., Creighton C.J., Han D.Y., Zariff A., Anderson M.L., Gunaratne P.H., Matzuk M.M. Functional microRNA involved in endometriosis. Mol. Endocrinol. 2011;25:821–832. doi: 10.1210/me.2010-0371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Braza-Boïls A., Mari-Alexandre J., Gilabert J., Sanchez-Izquierdo D., Espana F., Estelles A., Gilabert-Estelles J. MicroRNA expression profile in endometriosis: Its relation to angiogenesis and fibrinolytic factors. Hum. Reprod. 2014;29:978–988. doi: 10.1093/humrep/deu019. [DOI] [PubMed] [Google Scholar]
- 17.Nothnick W.B., Graham A., Holbert J., Weiss M.J. miR-451 deficiency is associated with altered endometrial fibrinogen alpha chain expression and reduced endometriotic implant establishment in an experimental mouse model. PLoS ONE. 2014;9:e100336. doi: 10.1371/journal.pone.0100336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Graham A., Falcone T., Nothnick W.B. The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival. Hum. Reprod. 2015;30:642–652. doi: 10.1093/humrep/dev005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Joshi N.R., Su R.W., Chandramouli G.V., Khoo S.K., Jeong J.W., Young S.L., Lessey B.A., Fazleabas A.T. Altered expression of microRNA-451 in eutopic endometrium of baboons (Papio anubis) with endometriosis. Hum. Reprod. 2015;30:2881–2891. doi: 10.1093/humrep/dev229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Nothnick W.B., Swan K., Flyckt R., Falcone T., Graham A. Human endometriotic lesion expression of the miR-144-3p/miR-451a cluster, its correlation with markers of cell survival and origin of lesion content. Sci. Rep. 2019;9:8823. doi: 10.1038/s41598-019-45243-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Li M., Zhou Y., Taylor H.S. miR-451a inhibition reduces established endometriosis lesions in mice. Reprod. Sci. 2019;26:1506–1511. doi: 10.1177/1933719119862050. [DOI] [PubMed] [Google Scholar]
- 22.Gao S., Liu S., Gao Z.M., Deng P., Wang D.B. Reduced microRNA-451 expression in eutopic endometrium contributes to the pathogenesis of endometriosis. World J. Clin. Cases. 2019;7:2155–2164. doi: 10.12998/wjcc.v7.i16.2155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Yang Y., Degranpré P., Kharfi A., Akoum A. Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J. Clin. Endocrinol. Metab. 2000;85:4721–4727. doi: 10.1210/jc.85.12.4721. [DOI] [PubMed] [Google Scholar]
- 24.Carli C., Metz C.N., Al-Abed Y., Naccache P.H., Akoum A. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: Involvement of novel kinase signaling pathways. Endocrinology. 2009;150:3128–3137. doi: 10.1210/en.2008-1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Veillat V., Carli C., Metz C.N., Al-Abed Y., Naccache P.H., Akoum A. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways. J. Clin. Endocrinol. Metab. 2010;95:403–412. doi: 10.1210/jc.2010-0417. [DOI] [PubMed] [Google Scholar]
- 26.Kats R., Metz C.N., Akoum A. Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J. Clin. Endocrinol. Metab. 2002;87:883–889. doi: 10.1210/jcem.87.2.8260. [DOI] [PubMed] [Google Scholar]
- 27.Akoum A., Metz C.N., Al-Akoum M., Kats R. Macrophage migration inhibitory factor expression in the intrauterine endometrium of women with endometriosis varies with disease stage, infertility status, and pelvic pain. Fertil. Steril. 2006;85:1379–1385. doi: 10.1016/j.fertnstert.2005.10.073. [DOI] [PubMed] [Google Scholar]
- 28.Khoufache K., Bazin S., Girard K., Guillemette J., Roy M.C., Verreault J.P., Al-Abed Y., Foster W., Akoum A. Macrophage migration inhibitory factor antagonists blocks the development of endometriosis in vivo. PLoS ONE. 2012;7:e37264. doi: 10.1371/journal.pone.0037264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., Delohery T., Chen Y., Mitchell R.A., Bucala R. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 2003;197:1467–1476. doi: 10.1084/jem.20030286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Nothnick W.B., Falcone T., Olson M.R., Fazleabas A.T., Tawfik O.W., Graham A. Macrophage migration inhibitory factor receptor, CD74 is overexpressed in human and baboon (Papio anubis) endometriotic lesions and modulates endometriotic epithelial cells survival and interleukin 8 expression. Reprod. Sci. 2018;25:1557–1566. doi: 10.1177/1933719118766262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Schwartz V., Krüttgen A., Weis J., Weber C., Ostendorf T., Lue H., Bernhagen J. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur. J. Cell. Biol. 2012;91:435–449. doi: 10.1016/j.ejcb.2011.08.006. [DOI] [PubMed] [Google Scholar]
- 32.Klasen C., Ohl K., Sternkopf M., Shachar I., Schmitz C., Heussen N., Hobeika E., Levit-Zerdoun E., Tenbrock K., Reth M., et al. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J. Immunol. 2014;192:5273–5284. doi: 10.4049/jimmunol.1302209. [DOI] [PubMed] [Google Scholar]
- 33.Jäger B., Klatt D., Plappert L., Golpon H., Lienenklaus S., Barbosa P.D., Schambach A., Prasse A. CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cell Signal. 2020;73:109672. doi: 10.1016/j.cellsig.2020.109672. [DOI] [PubMed] [Google Scholar]
- 34.Rodrigues D.A.S., Prestes E.B., Gama A.M.S., Silva L.S., Pinheiro A.A.S., Ribeiro J.M.C., Campos R.M.P., Pimentel-Coelho P.M., De Souza H.S., Dicko A., et al. CXCR4 and MIF are required for neutrophil extracellular trap release triggered by Plasmodium-infected erythrocytes. PLoS. Patholog. 2020;16:e1008230. doi: 10.1371/journal.ppat.1008230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Ruiz A., Salvo V.A., Ruiz L.A., Báez P., García M., Flores I. Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis. Reprod. Sci. 2010;17:894–903. doi: 10.1177/1933719110379920. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ruiz A., Ruiz L., Colón-Caraballo M., Torres-Collazo B.J., Monteiro J.B., Bayona M., Fazleabas A.T., Flores I. Pharmacological blockage of the CXCR4-CXCL12 axis in endometriosis leads to contrasting effects in proliferation, migration and invasion. Biol. Reprod. 2018;98:4–14. doi: 10.1093/biolre/iox152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Moridi I., Mamillapalli R., Cosar E., Sahin Ersoy G., Taylor H.S. Bone marrow stem cell chemotactic activity is induced by elevated CXCl12 in endometriosis. Reprod. Sci. 2017;24:526–533. doi: 10.1177/1933719116672587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.LeConte M., Chouzenoux S., Nicco C., Chéreau C., Arkwright S., Santulli P., Weill B., Chapron C., Dousset B., Batteux F. Role of CXCRL12-CXCR4 axis in the development of deep rectal endometriosis. J. Reprod. Immunol. 2014;103:45–52. doi: 10.1016/j.jri.2013.12.121. [DOI] [PubMed] [Google Scholar]
- 39.Tal A., Tal R., Kliman H.J., Taylor H.S. Loss of Cxcr4 in endometriosis reduces proliferation and lesion number while increasing intraepithelial lymphocyte infiltration. Am. J. Pathol. 2021;191:1292–1302. doi: 10.1016/j.ajpath.2021.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Shi X., Leng L., Wang T., Wang W., Du X., Li J., McDonald C., Chen Z., Murphy J.W., Lolis E., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25:595–606. doi: 10.1016/j.immuni.2006.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Meyer-Siegler K.L., Leifheit E.C., Vera P.L. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer. 2004;4:34. doi: 10.1186/1471-2407-4-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., Bucala R., Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J. Biol. Chem. 2008;283:2784–2792. doi: 10.1074/jbc.M703265200. [DOI] [PubMed] [Google Scholar]
- 43.Knudtson J.F., Tekmal R.R., Tellez Santos M., Binkley P.A., Krishnegowda N., Valente P., Schenken R.S. Impaired development of early endometriotic lesions in CD44 knockout mice. Reprod. Sci. 2016;23:87–91. doi: 10.1177/1933719115594022. [DOI] [PubMed] [Google Scholar]
- 44.Alali Z., Graham A., Swan K., Flyckt R., Falcone T., Cui W., Yang X., Christianson J., Nothnick W.B. 60S acidic ribosomal protein P1 (RPLP1) is elevated in human endometriotic tissue and in a murine model of endometriosis and is essential for endometriotic epithelial cell survival in vitro. Mol. Hum. Reprod. 2020;26:53–64. doi: 10.1093/molehr/gaz065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Nothnick W.B., Peterson R., Minchella P., Falcone T., Graham A., Findley A. The relationship and expression of miR-451a, miR-25-3p and PTEN in early peritoneal endometriotic lesions and their modulation in vitro. Int. J. Mol. Sci. 2022;23:5862. doi: 10.3390/ijms23115862. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.